image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 10 days, don't miss out!

Playetch - Debt repayment to save €20m by end next year

November 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • PTEC
  • Price:
  • 506p
Playtech’s interims were slightly ahead of expectations with revenues up 73% to €792m and EBITDA increasing 64% to €203.8m, ahead of guidance of c. €200m.Both B2B and B2C performed strongly. In B2B, revenues increased by 17% to €312m, with adjusted EBITDA of €77.2m. Americas was the main driver, with revenues +50% (+37% cc) to €69.8m, with Caliente once again underpinning this performance. Regulated Europe (ex-UK) was +39%, UK was +7% and  RoW + 53%. On the unregulated businesses, Asia declined by 22% with unregulated ex-Asia flat. The group now has over 300 brands on its SaaS offering having added 50 year-on-year.In B2C Snaitech is firing on all cylinders, with revenues +182% YoY, while adjusted EBITDA rose 154% to  €1 ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author